Purpose Fine-needle aspiration (FNA) cytology is a mainstay in the evaluation of thyroid nodules, but fails to reach reliable results in 25-30% of cases. The role of molecular markers in helping clinical decisions has been investigated for the last years, but their clinical usefulness is still unsettled. Methods Mutation analysis of BRAF, RAS genes and TERT promoter was performed in a series of 617 consecutive cytological specimens undergoing FNA. Results The 617 nodules had the following cytological diagnosis: non diagnostic 22 (3.6%), benign 425 (68.9%), indeterminate 114 (18.5%), suspicious 11 (1.8%) and malignant 45 (7.3%). BRAF mutations were found in 31 cases (5.0%), all but two in suspicious and malignant nodules. RAS mutations were detected in 47 samples (7.6%): 25 benign (5.9%) and 19 indeterminate nodules (16.7%). TERT promoter mutation alone was detected in three samples. Histological outcome was available for 167 nodules, 81 of which proved malignant: all the 48 with suspicious or malignant cytology; 25 out of 56 (44.6%) with indeterminate and 8 out of 57 (14%) with benign cytology. BRAF mutations were associated with worse tumors pathological features. The presence of RAS mutations was indicative of follicular-patterned malignancies in 5 out of 8 benign nodules and 9 out of 11 indeterminate nodules. Conclusions Our study established mutational rates for BRAF and RAS genes in a large series of FNA specimens. BRAF mutations were confirmed as highly specific but not able to improve cytological diagnosis, while RAS testing proved effective in assessing malignancy in nodules with indeterminate and benign cytology.
Introduction
Thyroid nodules are detected with increasing frequency in clinical practice. However, compared with the high incidence of thyroid nodular disease, malignant tumors of the thyroid are not common [1] . The cytological analysis of specimens obtained by fine-needle aspiration (FNA) allows to distinguish benign lesions from malignancies in 60-80% of thyroid nodules [2] . The remaining portion of nodules represents a clinical challenge, since they fall into a zone of vagueness that makes the clinical decision difficult. Considering that the risk of malignancy in indeterminate nodules ranges from 5 to 30% [3] , the majority of diagnostic surgeries would prove unneeded.
Classic variant of papillary thyroid carcinoma (CVPTC) shows marked cyto-nuclear and architectural atypia that are usually recognizable on cytological smears, allowing a cytological diagnosis of malignancy [4] . On the other hand, malignancies that are more frequently diagnosed as Bethesda III-IV on cytology are follicular-patterned tumors, namely follicular variant (FV) of PTC and follicular thyroid carcinoma (FTC) [5, 6] . Either benign and malignant thyroid tumors with follicular architecture share overlapping cyto-nuclear features that can cause misinterpretations at cytological level [7] . Moreover, differential diagnosis of these histotypes is often based on the evaluation of tumor's invasiveness, which can be assessed only at histological examination [8] .
Several molecular tests have been proposed as auxiliary instruments supporting cytological evaluation, mainly for Bethesda III to V categories. In particular, next-generation sequencing (NGS) gene panels, such as ThyroSeq, showed promising results on indeterminate nodules both in terms of positive predictive value (PPV) and negative predictive value (NPV) [9] . NGS testing requires specific laboratory equipments and it is still unclear whether clinical benefits justify its costs. In addition, PPV and NPV are not intrinsic properties of a test, but should be calculated on the basis of the pretest probability of malignancy, which considerably varies among studies, institutions and cytology categories [10] . As a consequence, the results obtained by a research group using a molecular test should not be extended to other conditions.
Our institution represents a national referral center for thyroid cytology, with a case load of more than 10,000 patients per year. The aim of this study was to establish the prevalence of mutations and the clinical role of molecular testing detected in a homogeneous and consecutive series of cytological specimens. The molecular analysis was conducted by cost-effective and widely used methodologies, such as high resolution melting analysis followed by direct sequencing. The genetic screening involved somatic point mutations in BRAF, HRAS, NRAS and KRAS. In a subset of cases mutational status of the promoter of TERT gene was also evaluated.
Materials and methods

Study population
Cases included in this study dated from June 2013 to September 2014. Cytological specimens were obtained consecutively at FNA from patients evaluated at the Unit of Endocrinology 1 of the University Hospital of Pisa (Italy) for solitary thyroid nodules or dominant nodules in multinodular goiter. This study was conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments; each patient signed an informed consent.
Fine needle aspiration cytology and histology
All FNAs were performed by the same operator (T.R.) according to the indication of guidelines [11, 12] . Cytological diagnosis was formulated independently and blindly by two cytopathologists (F.B and A.P.), following the indications of the Italian system [13] : TIR1 corresponds to Bethesda I, TIR2 to Bethesda II, TIR3 to Bethesda III and IV, TIR4 corresponds to Bethesda V and TIR5 to Bethesda VI. In the event of any discrepancy between the two readers a discussion was made to reach a consensus opinion and confirm the cytological category. During the study interval, information were collected regarding surgically resected nodules. Indication for thyroid surgery was independent of the results of molecular analysis. Histological diagnosis was rendered according to the WHO indication [14] and clinicalpathological tumor characteristics were collected. For the histological revision of encapsulated noninvasive FVPTC, only cases submitted to a complete sampling of tumor capsule have been considered for their eventual reclassification as noninvasive follicular neoplasm with papillary-like nuclear features (NIFTP) [15] .
Sample preparation and DNA purification
Residual material from FNA has been recovered by rinsing the syringe with phosphate-buffered saline flushing the fluid repeatedly into a clean tube. Cell pellets obtained by mild centrifugation were immediately used for DNA purification or stored at − 20 °C until DNA extraction. DNA was purified using QIAamp DNA Mini kit (Qiagen, Hilden, Germany), following the manufacturer's instructions. DNA quality and quantity were evaluated by a spectrophotometer (NanoDrop 1000, Thermo Fisher Scientific, Wilmington, DE, USA). Whenever the DNA concentration was higher than 10 ng/ μl, samples underwent dilution with nuclease-free water.
Molecular testing
Molecular analysis was performed blindly to the cytological results. Samples were analyzed for the presence of molecular alterations in BRAF (exon 15), NRAS (exon 3), HRAS (exon 3) and KRAS (exon 2) genes. A real-time PCR was set-up using a pre-prepared reaction mix (Hot StarTaq Master Mix, Qiagen), a DNA-binding dye (EvaGreen, Biotium Inc., Fremont, CA, USA) and specific primer pairs [16] . Reactions were performed using 4 μl DNA. After PCR reaction, products were evaluated by high resolution melt (HRM) analysis. Melt curves of samples were compared with that of known positive and negative controls, included in each experiment together with a no template control. For samples with altered melt curves, PCR products were purified and analyzed by direct sequencing on a AbiPrism 3130 Genetic Analyzer (Applied Biosystem, Foster City, CA, USA).
The analysis of TERT promoter was performed by PCR followed by direct sequencing [17] in a subset of cases, in particular in all the nodules with TIR3, TIR4, TIR5 cytology and later also on TIR1 and TIR2 nodules positive for BRAF or RAS mutations.
Statistical analysis and test performance
The presence of statistical correlations among the considered parameters was evaluated using Statistica Software (Dell Software, Round Rock, TX, USA) as follows: χ 2 and Fisher's exact tests for categorical variables; t test for quantitative variables (after assessment of the normal distribution of the continuous variables). Statistical significance was set at p < 0.05. Three groups have been made up: BRAF mutant, RAS mutant (HRAS, NRAS and KRAS considered together) and wild-type cases: statistical comparisons have been performed between BRAF mutant versus wild-type and between RAS mutant versus wild-type.
Performance of molecular test was obtained for TIR3 nodules by calculating specificity, sensitivity, PPV and NPV as reported previously [18] . In the case that an encapsulated FVPTC was reclassified as NIFTP, in calculating the performance of molecular test it was anyway considered as malignant, due to the fact that NIFTPs have surgical indication.
Results
Study population, cytology and molecular analysis
A total of 583 patients with 680 nodules were enrolled during the study interval. Sixty-three out of 680 samples were not included in the analysis of data, since they were irrelevant for the purpose of the study (31 hyperplastic lymph nodes, 11 metastatic lymph nodes, 9 lymphocytic thyroiditis, 3 lymphomas, 1 Schwannoma and 8 cystic non diagnostic nodules). They were screened for molecular alterations, being analyzed blindly, and were wild-type for all the markers, except for 4 metastatic lymph nodes that were BRAFmutated and one sample that was inadequate.
The final series included 617 cytological samples from 511 patients, 112 males (21.9%) and 399 females (78.1%) (sex ratio 1:3.6). Patients' mean age was 48.9 years ± 14.3 (males 50.8 years ± 13.9; females 48.3 years ± 14.4). Mean nodules size was 26.0 mm ± 13.4.
Cytological diagnosis of the 617 FNAs was: non diagnostic, TIR1 n = 22 (3.6%); benign, TIR2 n = 425 (68.9%); indeterminate, TIR3 n = 114 (18.5%); suspicious for malignancy, TIR4 n = 11 (1.8%); malignant, TIR5 n = 45 (7.3%) ( Table 1) .
BRAF mutation was found in 31 out of 617 samples (5.0%) and in particular in 1 TIR2, 1 TIR3, 3 TIR4 and in 26 TIR5 nodules (Table 1) . Among the 31 BRAF mutations, 30 were p.V600E and one was p.K601E (in a TIR2 nodule).
Overall RAS mutations were found in 47 out of 617 samples (7.6%) and in particular in 1 TIR1, in 25 TIR2, in 19 TIR3 and in 2 TIR4 nodules (Table 1) . NRAS mutation was detected in 36 out of 47 samples (p.Q61R in 32 and p.Q61K in 4 cases), HRAS mutation was found in 7 (3 p.Q61R and 4 p.Q61K mutations) and KRAS mutation in four samples (2 p.G12V, 1 p.G12D and 1 p.G13D).
Among the 170 TIR3, TIR4 and TIR5 nodules, TERT promoter mutation was found in eight cases (4.7%) (data not shown in Table 1 ), in particular in 1 TIR3, 1 TIR4 (also mutated for NRAS p.Q61R), and 6 TIR5 (3 also BRAF p.V600E mutated). All these cases had the C228T substitution. No TERT promoter mutations have been detected in TIR1 and TIR2 nodules with BRAF or RAS mutations.
Cytology vs histology
Histological outcome was available for 167 nodules from 126 patients (34 males and 92 females, sex ratio 1:2.7) who underwent surgery. Mean age of patients was 44.1 years ± 14.7. Table 2 reports cytological diagnosis according to the histology. Overall, 81 out of 167 nodules (48.5%) were malignant on histology: 71 PTC (87.7%), 9 FTC (11.1%), Indication for surgery was the cytological diagnosis of suspicious or malignant nodules in 48 patients, all of them having a final histology of malignancy. Eight nodules with TIR4 or TIR5 cytology are missing in the surgical cohort since seven patients with eight nodules were lost to follow-up after FNA. Out of 114 patients with indeterminate cytology, surgery was performed in 56 patients, 12 of whom had a nodule size > 40 mm and 44 had nodules with one or two suspicious ultrasonography features as irregular margins, microcalcifications, marked hypoechogenicity. Among these 56 indeterminate nodules 25 proved malignant (44.6%) with a histological diagnosis of CVPTC (n = 2), FVPTC in (n = 14), FTC in (n = 7), solid variant (SV) PTC (n = 2). Forty patients with 57 nodules with a benign cytology were submitted to surgery for the following indications: large nodule size causing pressure symptoms (n = 24); presence of suspicious ultrasonographic features (n = 8), and/or coexistence with another nodule with indeterminate (n = 5), suspicious (n = 1) or malignant (n = 2) cytology. The rate of malignancy among TIR2 nodules was 14.0%, since 8 out of 57 nodules proved malignant, the majority of them being FVPTC (see Table 2 ). Out of 22 patients with a non-diagnostic cytology, 6 were submitted to surgery for large nodule size or multinodular goiter; all of them proved benign.
Molecular results according to cytology and histology
All the six resected TIR1 nodules were wild-type; the patient with the NRAS-mutated TIR1 nodule was not operated.
Out of the 57 TIR2 nodules submitted to surgery 52 were wild-type, with a benign histology in 49 and carcinoma in 3. Five were RAS mutated, all of them having a histology of FVPTC (Fig. 1) .
Of the 56 TIR3 nodules submitted to surgery, one had BRAF mutation, and was a CVPTC at histology; 11 were RAS mutated, 2 benign and 9 malignant; one nodule had TERT promoter mutation alone and was a FTC at histology; finally, 43 nodules were negative for mutations, 29 benign and 14 malignant (Fig. 2) . The malignancy yield in RASmutant TIR3 nodules (82%) was significantly higher than in wild-type ones (33%) (p = 0.003).
Of the 48 TIR4 and TIR5 nodules submitted to surgery: 18 were wild-type, 11 CVPTC, 4 FVPTC, 1 SVPTC and 2 FTC; 25 nodules had BRAF mutation, 20 CVPTC (of these two had coexistence of BRAF and TERT promoter mutations), 4 TCVPTC, 1 FVPTC; 2 were RAS-mutated, 1 FVPTC and 1 ATC (that had also the TERT C228T mutation); 3 nodules had TERT promoter mutation alone and all of them were CVPTC.
Overall, in the surgical cohort there were 26 FVPTC: 5 infiltrative (19.2%); 7 encapsulated with invasion of tumor capsule (26.9%); 14 encapsulated noninvasive (53.9%). Eleven out of the 14 encapsulated noninvasive FVPTC had been submitted to a complete sampling of the tumor capsule and were therefore considered for reclassification: only four of them (36.4%) met the NIFTP cyto-nuclear requirements. The mutational status of all FVPTC is reported in Fig. 3 .
Test performance and statistical analysis
In indeterminate nodules the mutation testing showed specificity 94%, sensitivity 44%, PPV 85.5% and NPV 67.6%. The reported specificity and sensitivity of the ThyroSeq test [9, 19] were used as a basis for comparison to built a graph representing how the PPV of both tests varies according to prevalence of malignancy (Fig. 4) . In the entire surgical cohort, the presence of any type of mutation in cytology was highly predictive for malignancy at histology (p < 0.0001). Either BRAF mutations (p < 0.0001) and RAS family mutations (p value 0.0003) by themselves showed a high PPV.
Clinical-pathological characteristics of malignant lesions are reported in detail in Table 3 . RAS mutations were not significantly associated with pathological characteristics of tumors, while BRAF mutations correlated with infiltration of tumor capsule, invasion of thyroid parenchyma, invasion of thyroid capsule, infiltration of extra-thyroidal soft tissue, multifocality and regional lymph node involvement at presentation. Since only seven cases had TERT promoter mutation, this molecular marker has not been considered in the statistical analysis.
Discussion
According to the latest guidelines of the American Thyroid Association [20] , a molecular test proves to be clinically convenient whenever its application improves patient outcome. It is still debated whether a wide incorporation of molecular testing into clinical practice would result in a significant improvement of the performance of cytology [10] . However, the role of molecular tests as ancillary instruments in the perioperative decision making is becoming increasingly accepted [9, 21] , even if the high cost leads controversy related to cost-effectiveness issues [22] [23] [24] . Another crucial point limiting a wide use of molecular tests on thyroid cytology is the fact that PPV and NPV are calculated on the basis of pretest prevalence of malignancy, which varies considerably among institutions [10, 25] . Therefore, an overall assessment of clinical utility of specific molecular tests cannot be reliably rendered.
Herein the results of molecular testing in a homogeneous series of 617 thyroid nodules are presented. The distribution of nodules cytology among each diagnostic category showed The graph PPV/prevalence of malignancy shows three PPV curves: the red curve corresponds to the molecular test performed in this study; the green and blue curves are referred to the results previously obtained with ThyroSeq for Bethesda III and IV nodules respectively [9, 19] a good concordance with other reports [11, 12] , thus indicating that our cohort was representative of a rather homogeneous series.
BRAF and RAS mutations were tested in all the samples giving us the opportunity to evaluate the clinical usefulness of mutational analysis in addition to cytology. The overall frequency of BRAF mutation was 5.0%, while RAS genes were mutated in 7.6% of cases. Although few studies were performed in unselected series of thyroid cytology, our results are comparable with those of Moses and collaborators who reported a frequency of 5.8% for BRAF mutations and 5.3% for NRAS mutations in a series of 400 thyroid nodules [26] . TERT promoter mutations were tested in TIR3, TIR4, TIR5 (n = 170), and found in 4.7% of cases. Similar results have also been obtained by Decaussin-Petrucci and colleagues, who reported TERT promoter mutations in 3% of cases among 326 indeterminate, suspicious and malignant nodules [27] .
In our series histology was available in 167 nodules. Cytology was confirmed to be the cornerstone of diagnosis, since all the 48 cytologically suspicious and malignant nodules were malignant on final histology. As a consequence, positivity for any mutation could not increase the diagnostic accuracy of cytology in TIR4 and TIR5 categories. BRAF was highly specific, being found almost exclusively in TIR4 and TIR5 categories, but had a lower sensitivity with respect to cytology, being found in 52.1% of these nodules. On the other hand, BRAF mutations were statistically associated with clinical-pathological features of tumor aggressiveness, such as extra-thyroidal extension and regional nodes metastases, in line with the current literature [28, 29] . Our results confirm that BRAF mutations detected on cytology, although not sufficiently sensitive, can give useful supplemental information guiding clinical decisions.
As already well established, also cytology, although highly specific, was confirmed to be not sufficiently sensitive for malignancy, as 8 out of 57 TIR2 and 25 out of 56 TIR3 nodules were found to be cancers at histology. In the present study the rate of malignancy at histology in indeterminate nodules was rather high (44.6%). This is conceivably due to the careful selection of patients submitted to surgery made in our institution, based on clinically suspicious features. Even more importantly, in the group with TIR2 cytology, 57 nodules in 40 patients out of 425 nodules in 335 patients were selected for surgery for clinical suspicion. This explains the high malignancy rate (14%) observed also in the TIR2 class. Comparable results have been obtained by other researchers [30] [31] [32] . Indeed, surgical outcome is essential to make a reliable evaluation of molecular screening on cytology, but surgical cohorts are necessarily biased by selection effects. This bias causes a difficulty in evaluating the real risk of malignancy found among benign and indeterminate cytology.
As expected, the vast majority of malignancies hidden into benign and indeterminate categories were follicularpatterned neoplasm, namely FVPTC and FTC. BRAF was not useful in TIR3 and TIR2 classes being found in only one indeterminate nodule (0.9%), that was a CVPTC, and in one benign nodule (0.2%). This last case does not represent necessarily a false negative of cytology, since the mutation was a p.K601E that can be found, although rarely, also in benign thyroid tumors [33, 34] ; indeed patient was not operated. The BRAF mutation frequency that we observed in TIR3 category is less than 1%: this is in line with the results of other prospective studies conducted in Europe on unselected series of indeterminate nodules, which report a rate of 0-2.3% [35] [36] [37] .
Although poorly sensitive, a clinical usefulness was found for RAS mutations. These were detected in the 5.9% of TIR2 and 16.7% of TIR3 nodules. Only five RAS-mutant TIR2 nodules have been so far submitted to surgery, and all of them proved FVPTC. On the other hand, only three out of 52 wild-type TIR2 were malignant on histology. Therefore, in TIR2 category RAS testing was highly predictive for malignancy. These data suggest that clinical factors and molecular results can work together in the identification of subgroups of nodules that despite a benign cytology have a high risk of malignancy.
In indeterminate nodules that were surgically removed, without considering one BRAF-mutant nodule and one TERT-mutant nodule, malignancy rates observed in RASmutant and RAS-wild-type groups were outstandingly different, 82 and 33% respectively. Therefore, although in the surgical cohort RAS mutations did not show statistical associations with clinical-pathological risk factors, RAS-mutant indeterminate nodules had a significantly higher probability to hide a cancer than RAS wild-type cases. Here two main aspects deserve discussion. First, malignancy rate among wild-type indeterminate nodules (33%) was lower than that observed without considering molecular analysis (44.6%), but it was still too high to safely consider an approach merely based on clinical observation. When a good molecular test on cytology is negative, the risk of malignancy should be comparable to that of benign cytology [23] . On the other hand, given the pretest probability of malignancy of 44.6%, the performance of our molecular test in terms of PPV (85.5%) would not have been far different from performance rates of already available NGS-based tests (Fig. 3) , although these tests demonstrated a much higher NPV compared to our study. Therefore, beyond limitations due to the high pretest malignancy rate observed in our cohort, and after further validations, our molecular panel could effectively work as a rule-in test for malignancy.
TERT promoter mutations were found in 7 of 56 TIR4 and TIR5 (12.5%) and in only 1 TIR3 nodule out of 114 (0.9%). Thus TERT mutations on cytology were diagnostic in only one case and an extensive screening for these alterations did not prove cost-effective. Similar results were obtained by other groups [27, 38] .
In summary, we herein provide a reliable picture of the prevalence and distribution of the most frequent somatic mutations in an unselected series of cytological samples. All TIR4 and TIR5 samples proved malignant at histology. Therefore BRAF analysis could not further improve the diagnostic accuracy of cytology in these classes of cytology. On the other hand it was found in only 1 out of 56 TIR3 nodules that was a CVPTC at histology. This indicates that BRAF analysis would prove uninformative in more than 99% of TIR2 and TIR3 nodules. Anyway BRAF may have a role as a prognostic marker.
RAS mutations in indeterminate cytology showed a high predictive value for follicular-patterned malignancies. In benign cytology RAS mutations were not so prevalent (5.9%) but highly specific for malignancy. Therefore, to result cost-effective, RAS analysis in benign cytology should be conducted only in carefully selected nodules.
In conclusion, our results show that even using a cheap methodology and analyzing a restricted panel of markers, molecular testing on indeterminate nodules and selected benign nodules can represent an effective tool supporting routine cytology evaluation. On the contrary, a thorough molecular evaluation of benign, suspicious and malignant cytology specimens does not prove worthwhile. For these reasons, endocrinologists and pathologists should decide in cooperation which patients could more likely benefit from an adjunctive molecular approach.
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